BCIQ Profiles

Company Profile Report

Lilly looks to expand Cyramza's label into first-line NSCLC

Eli Lilly said it plans to initiate global regulatory applications mid-year seeking to expand the label of Cyramza ramucirumab to include first-line treatment of metastatic non-small

Read the full 263 word article

How to gain access

Continue reading with a
two-week free trial.